Why Did MiNK Therapeutics (INKT) Stock Jump 50% Premarket Today?

Shares of MiNK Therapeutics (NASDAQ: INKT) surged roughly 60% in premarket trading on Tuesday, March 10, 2026, after the clinical-stage biopharmaceutical company announced a major collaboration with C-Further, an international pediatric oncology consortium, to develop a new cell therapy targeting childhood cancers.

The deal brings non-dilutive funding and a potential share of future commercial revenues, giving investors a rare piece of good news for a stock that has struggled over the longer term. The announcement marks one of the first programs selected by C-Further since its launch, signaling strong early validation of MiNK’s technology platform.

Collaboration Targets Hard-to-Treat Childhood Cancers

MiNK Therapeutics announced it has been selected as one of the first industry partners by C-Further, a consortium backed by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. Together, they will develop a new type of immune cell therapy designed to target a protein called PRAME, a marker found on the surface of several childhood cancers, including bone tumors (sarcomas), a type of blood cancer (acute myeloid leukemia), and a brain tumor known as medulloblastoma. These are cancers where treatment options are often limited, especially after relapse, making new approaches urgently needed.

Under the terms of the deal, MiNK will receive up to approximately $1.1 million in non-dilutive funding — meaning the company won’t have to issue new shares to raise the money, avoiding dilution for existing shareholders. Payments are tied to hitting specific scientific milestones as the program progresses.

The agreement also entitles MiNK to a meaningful double-digit percentage of any future commercial revenues generated by the therapy, providing long-term upside potential if the treatment eventually reaches patients.

Importantly, the deal is non-exclusive, so MiNK retains full freedom to pursue other partnerships and cancer indications independently. Preclinical research will be led by scientists at the University of Southampton, who will test the therapy’s safety and effectiveness across multiple pediatric cancer models before advancing toward human trials.

Join our Telegram group and never miss a breaking digital asset story.

INKT Stock Brief: Premarket Surge and Key Metrics to Know

As of premarket trading on the morning of March 10, 2026 (8:27 AM EDT), INKT shares were trading at $16.60 — up $6.15, or approximately 58.85%, from the prior session’s closing price of $10.28. The stock had opened and closed the previous day at $10.28, within a 52-week range of $6.34 to $76.00, reflecting just how volatile this small-cap biotech has been.

The company’s market cap stood at roughly $49 million as of March 9, with average daily trading volume of around 11,000 shares, meaning today’s move is likely to attract significant attention from traders watching thinly traded biotech names.

From a fundamentals standpoint, INKT remains a pre-revenue, clinical-stage company, with a trailing earnings per share of -$3.01 and a net loss of approximately $12.4 million over the past twelve months. Total cash on hand was $14.28 million as of the most recent quarter, and the company has no dividend.

Analysts covering the stock have an average price target of $39.00, with the highest target sitting at $43.00, suggesting significant upside from recent levels even before today’s pop. The most recent analyst action came from HC Wainwright & Co., which upgraded INKT to Buy in August 2025 with a $35 price target. Over the past year, INKT has returned roughly +27%, though it remains down sharply over three- and five-year periods compared to the broader market.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.